Sonrotoclax is under development for the treatment of relapsed and refractory multiple myeloma, B-cell malignancies such as nodal, extranodal, splenic marginal zone lymphoma, mantle cell lymphoma, ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

The agency also approved acalabrutinib as part of combination therapy for mantle cell lymphoma. The FDA approved two oncology regimens on Jan. 16. One is for a subset of patients with colorectal ...

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell ... arm.

3 Michael Wang, MD, Puddin Clarke Endowed Professor, Director of Mantle Cell Lymphoma ... arm receiving treatment with a BTK inhibitor on relapse or disease progression. The safety and tolerability of ...

Intravascular large B-cell lymphoma (IVLBCL) is a rare and highly malignant non-Hodgkin B-cell lymphoma with uncommon clinical presentation and poor prognosis. The diagnostic pitfall of IVLBCL is ...

Skin infections also develop when you have open wounds or scratch frequently. Some patients who have advanced cutaneous T-cell lymphoma die of an infection. That’s why it’s so important to be under ...

Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen ...